Success Stories: NAILG Helps Scientist Secure NIW for Work in Affordable Drug Technologies

Client’s Testimonial:

“Super exciting! Thank you for the update. I have left a 5-star review on the review page. Appreciate your responsiveness and solid work throughout the process!”

On February 5^th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Scientist in the Field of Bioengineering (Approval Notice).

General Field: Bioengineering

Position at the Time of Case Filing: Scientist

Country of Origin: China

State of Residence at the Time of Filing: Washington

Approval Notice Date: February 5^th, 2025

Processing Time: 1 year, 4 days (Premium Processing Requested)

Case Summary:

We are pleased to highlight the approval of an EB-2 NIW (National Interest Waiver) petition for a bioengineering expert whose research is accelerating the development of cost-effective protein-based therapeutics. At the time of filing, our client was an active researcher whose contributions were already helping reshape how novel protein drugs are discovered and delivered.

Driving Innovation in Therapeutic Development:

Our client’s proposed endeavor focuses on advancing computational algorithms and experimental screening techniques that streamline the creation of modular, low-cost, and efficient protein therapeutics. This line of research addresses significant limitations in the current pharmaceutical landscape, particularly the high cost and distribution challenges associated with protein drugs like antibodies and insulins.

By tackling the issues of cold-chain transportation, where refrigeration equipment, energy needs, and air freight costs sharply drive up expenses, his work promises to eliminate barriers to access and reduce the financial strain on both patients and healthcare systems. The development of new protein drugs with greater stability and lower production demands stands to broaden access to life-saving therapies for under-resourced populations.

Significant Scholarly Output:

The petitioner’s accomplishments include:

6 peer-reviewed journal articles (1 first-authored)
2 preprints (1 first-authored)
A total of 458 citations to his published research

His work has earned notable recognition, including research funding from the National Institute of Allergy and Infectious Diseases, National Institute on Aging, Department of Defense, National Institutes of Health, and the Cystic Fibrosis Foundation, reinforcing the national relevance of his contributions.

Expert Endorsements:

One expert noted:

“It is therefore clear that [client] has made substantial contributions that go beyond creating a single new cancer treatment delivery platform, an impressive achievement by itself, and has also improved fundamental aspects of drug testing methodology.”

This endorsement reflects the lasting impact of his scientific achievements and highlights his unique value to the United States’ biomedical research ecosystem.

Conclusion:

This NIW approval follows the client’s earlier EB1B success, also secured through NAILG’s representation. We are proud to support researchers whose work directly improves the accessibility and affordability of essential medicines. NAILG congratulates this client once again and looks forward to witnessing his continued contributions to therapeutic innovation and public health in the U.S.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.